Identification of mimotopes with diagnostic potential for Trypanosoma brucei gambiense variant surface glycoproteins using human antibody fractions

• Published in: PLoS neglected tropical diseases Vol. 6; no. 6; p. e1682
• Main Authors: Van Nieuwenhove, Liesbeth, Büscher, Philippe, Balharbi, Fatima, Humbert, Michael, Dieltjens, Tessa, Guisez, Yves, Lejon, Veerle
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.06.2012; Public Library of Science (PLoS)
• Subjects: Antibodies; Antibodies, Protozoan - blood; Antigens; Clinical Laboratory Techniques - methods; Epitopes; Genetic aspects; Genetic variation; Glycoproteins; Humans; Identification and classification; Immune system; Medicine; Monoclonal antibodies; Parasites; Parasitology - methods; Patients; Peptides; Polyclonal antibodies; Properties; Proteins; Protozoa; Tropical diseases; Trypanosoma brucei; Trypanosoma brucei gambiense - immunology; Trypanosomiasis, African - diagnosis; Variant Surface Glycoproteins, Trypanosoma - immunology; Vector-borne diseases; Viral antibodies; Belgium; Parasitology; Peptides; Clinical Laboratory Techniques; Humans; Variant Surface Glycoproteins, Trypanosoma; Antibodies, Protozoan; Trypanosomiasis, African; Epitopes; Trypanosoma brucei gambiense
• ISSN: 1935-2735; 1935-2727; 1935-2735
• DOI: 10.1371/journal.pntd.0001682

At present, screening of the population at risk for gambiense human African trypanosomiasis (HAT) is based on detection of antibodies against native variant surface glycoproteins (VSGs) of Trypanosoma brucei (T.b.) gambiense. Drawbacks of these native VSGs include culture of infective T.b. gambiense trypanosomes in laboratory rodents, necessary for production, and the exposure of non-specific epitopes that may cause cross-reactions. We therefore aimed at identifying peptides that mimic epitopes, hence called "mimotopes," specific to T.b. gambiense VSGs and that may replace the native proteins in antibody detection tests. A Ph.D.-12 peptide phage display library was screened with polyclonal antibodies from patient sera, previously affinity purified on VSG LiTat 1.3 or LiTat 1.5. The peptide sequences were derived from the DNA sequence of the selected phages and synthesised as biotinylated peptides. Respectively, eighteen and twenty different mimotopes were identified for VSG LiTat 1.3 and LiTat 1.5, of which six and five were retained for assessment of their diagnostic performance. Based on alignment of the peptide sequences on the original protein sequence of VSG LiTat 1.3 and 1.5, three additional peptides were synthesised. We evaluated the diagnostic performance of the synthetic peptides in indirect ELISA with 102 sera from HAT patients and 102 endemic negative controls. All mimotopes had areas under the curve (AUCs) of ≥0.85, indicating their diagnostic potential. One peptide corresponding to the VSG LiTat 1.3 protein sequence also had an AUC of ≥0.85, while the peptide based on the sequence of VSG LiTat 1.5 had an AUC of only 0.79. We delivered the proof of principle that mimotopes for T.b. gambiense VSGs, with diagnostic potential, can be selected by phage display using polyclonal human antibodies.